Management Team

Clay Siegall, Ph.D.

President & Chief Executive Officer

Clay Siegall, Ph.D.
President & Chief Executive Officer

Dr. Siegall previously served as the CEO and President of Seagen, Inc., which he co-founded in July 1997. Under his nearly 25 years of leadership, Seagen became the world leader in ADC therapeutics, earned FDA approvals for four cancer therapies, and grew to over $2 billion in annual revenue. During his tenure, he raised well over $1 billion of financing for Seagen from public and private markets and oversaw the company’s acquisition of Cascadian Therapeutics. Pfizer, Inc. agreed to purchase Seagen for $43 billion in March 2023. Prior to Seagen, Dr. Siegall worked in positions of increasing responsibilities at Bristol Myers Squibb and previously at the National Cancer Institute. He earned a PhD in Genetics at George Washington University and a B.S. in Zoology at the University of Maryland.

Jack Higgins, Ph.D.

Chief Scientific Officer

Jack Higgins, Ph.D.
Chief Scientific Officer

Dr. Jack Higgins is a biotechnology leader with over a decade of experience. He previously spent 11 years at Molecular Templates, Inc., serving in roles of increasing responsibility before being appointed Chief Development Sciences Officer. During his time at Molecular Templates, Dr. Higgins led discovery and development efforts for multiple clinical candidates and co-invented the company’s Engineered Toxin Body (ETB) platform. Dr. Higgins completed a fellowship in tumorimmunology at the National Cancer Institute. He holds a Ph.D. and M.S from the University of Arkansas and a B.S.from Texas A&M University. 

Kinney Horn

Chief Business Officer

Kinney Horn
Chief Business Officer

Kinney Horn has over twenty years of experience in life science finance, leadership, operations, and biopharmaceutical Business Development roles, representing over $30B in transactions. Prior to joining Immunome, Mr. Horn was Chief Business Officer of Olema Oncology, where he was part of the team that completed the company’s $85M Series C crossover financing round and $240M IPO. Before Olema, he was an Entrepreneur in Residence at EcoR1 Capital.

Mr. Horn spent 16 years at Genentech, where his transaction experience included leading teams from of up to 50 employees in identifying pre-clinical and clinical stage opportunities, structuring strategic alliances, negotiating and closing deals, and managing contractual relationships. His international experience includes negotiations with European and Asian companies. In addition to corporate transaction responsibilities, he led the annual oncology strategic sourcing process for 13 areas of oncology research and development.

Prior to Roche’s acquisition of Genentech, Mr. Horn worked with early-stage biotechnology companies that Genentech had invested in through GenenFUND, Genentech’s private equity fund; and began his career in various investment banking and venture roles. Mr. Horn has degrees in economics, international affairs and biochemistry from Mary Washington College and Georgetown University.

Bob Lechleider, M.D.

Chief Medical Officer

Bob Lechleider, M.D.
Chief Medical Officer

Prior to joining Immunome, Dr. Lechleider was the Chief Medical Officer at OncoResponse, where he oversaw the development of the company’s proprietary oncology pipeline. Before OncoResponse, Dr. Lechleider served as the Senior Vice President of clinical development for Seagen, where he was responsible for directing the development of the early and late-stage portfolios, including the successful initial licensing of Padcev® for the treatment of previously treated metastatic urothelial cancer.

Dr. Lechleider began his biotech career at MedImmune (an Astra Zeneca company) and went on to positions of increasing responsibility at Human Genome Sciences and Macrogenics before heading development at Seagen. Prior to his career in biotech, Dr. Lechleider held academic positions where he studied basic cellular and molecular biology.

Dr. Lechleider earned his A.B. from Princeton University and his M.D. from the University of Illinois College of Medicine at Chicago before receiving his clinical residency in internal medicine at Beth Israel-Deaconess Medical Center in Boston, and later in medical oncology at the National Cancer Institute (NCI) in Bethesda.

Max Rosett

Chief Financial Officer

Max Rosett
Chief Financial Officer

Max Rosett initially joined Immunome in October 2023 at the close of the company’s merger with Morphimmune. He previously served in roles of increasing responsibility as Morphimmune, concluding as Acting Chief Operating Officer. Prior to Morphimmune, Mr. Rosett was a Principal at Research Bridge Partners, a life science investment firm. He has also worked as a software engineer at Google, and he started his career at the Boston Consulting Group, where he served clients in the pharmaceutical industry. Mr. Rosett earned a M.S. in Computer Science from Georgia Institute of Technology and a B.A. in Mathematics from Yale University.

Sandra Stoneman, J.D. 

Chief Legal Officer

Sandra G. Stoneman
Chief Legal Officer and Corporate Secretary

Sandra G. Stoneman is the Chief Legal Officer and General Counsel of Immunome. In this role, Sandra serves as Corporate Secretary to the Board of Directors and leads the legal, corporate governance, intellectual property and human resources functions of the company. Sandra structures, negotiates and documents the company’s collaborations, partnerships, licenses and strategic and financing transactions. She is a seasoned legal advisor, with more than 20 years of experience advising high-growth companies in the life sciences, medical technologies and high-tech sectors. Prior to her role at Immunome, Sandra was an attorney at the law firms of Duane Morris LLP and Dechert, and is a 1997 magna cum laude graduate of Temple University School of Law, where she was an articles editor for the Temple Law Review, and a summa cum laude graduate of the State University of New York at Binghamton. Sandra has received numerous accolades for her transactional work in the life sciences field, including being continuously listed in U.S. News/Best Lawyers, Chambers USA, LMG Life Sciences and IFLR1000, and being named an Influencer of the Law by The Philadelphia Inquirer, a Best of the Bar by The Philadelphia Business Journal and a Top USA Woman Dealmaker by Global M&A Network.

Bruce Turner, M.D., Ph.D.

Chief Strategy Officer

BruceTurner, M.D., Ph.D.
Chief Strategy Officer

Dr. Turner previously founded several biotechnology companies including Xanadu Bio and Gennao Bio, where he has served in executive positions including Chief Executive Officer and President. During his tenure at these companies and others he has successfully raised more than $100M of financing despite challenging market conditions. Dr. Turner previously spent 5 years at Hoffman La-Roche with increasing responsibility for drug development in the areas of metabolic diseases and oncology. Recently, Dr. Turner was a managing director at Boxer Capital of the Tavistock Group and Bank of American Merrill Lynch. Dr. Turneris the author of more than 40 publications primarily in areas of breast cancer and signal transduction. He completed his undergraduate education at the University of Chicago and graduated from University of Pennsylvania School of Medicine with M.D and Ph.D. degrees. Dr. Turner completed a residency in Radiation Oncology at Yale University.